The Lundbeck and Novo-backed cancer therapy developer priced its shares at the bottom of their range in an upsized offering.

SoftBank led the companionship service provider's latest round, pushing its total funding to $240m.

Tencent, Charles River Laboratories and National Resilience all backed the stem cell technology developer’s series B round.

Ubicom Holdings Japan helped gynaecological imaging software developer Illumigyn take its total funding to $33m while Optum took part in a $30m round for health payment technology provider Medallion.

The wearable glucose monitor developer’s nine-figure series B round included M Ventures, Hikma Ventures, Axa Investment Management, Ascencia, Hikm Taisho, Cirrus Logic and EOFlow.

Alphabet returned to reinvest in the epigenetics diagnostics technology developer through a series D round that took its total funding to about $145m.

Bristol Myers Squibb was among the participants in cellular therapy developer Clade Therapeutics' series A round, with the proceeds to go to platform development.

Cancer drug developer Parthenon Therapeutics secured the funding in a series A round co-led by Pfizer Ventures and Taiho Ventures.

Cox Enterprises invested in digital media company Axios at a $430m valuation while Bristol Myers Squibb helped enzyme drug developer Nitrase Therapeutics boost its series A round to $45m.

Gilead and BeiGene participated in a round for the immuno-oncology therapeutics developer in a round that came seven months after it raised $43m.